BioSpace News Archive

Four separate research reports presented at premier Alzheimer’s disease and aging conferences add to the increasing set of details about the accuracy and clinical usefulness of the PrecivityAD™ blood test from C2N Diagnostics.

Bacainn Therapeutics, Inc., a biotechnology company focused on developing novel therapies that target the innate immune system to address uncontrolled inflammation, today announced that Ashley Mansell, PhD, Senior Director of Research & Development, Bacainn Therapeutics & Principal Investigator, Hudson Institute of Medical Research, will present at the 3rd Inflammasome Therapeutics Summit being held virtually on November 16 – 18.

InnoCare Pharma, a leading biotech company, announced that the company executives will attend the upcoming investor conferences organized by Goldman Sachs and Morgan Stanley to share company’s latest development.

RELIEF THERAPEUTICS Holding SA reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., has issued a press release announcing receipt of the U.S. Food and Drug Administration’s response to NRx’s October 8, 2021 submission of updated manufacturing information for aviptadil.

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that clinical data of LUMEVOQ® and GS030 gene therapies will be presented at the 125th Annual Meeting of the American Academy of Ophthalmology in New Orleans, Louisiana.

Nanoform, an innovative nanoparticle medicine enabling company, announced it has received ISO/IEC 27001:2013 certification for its Information Security Management System.

Athersys reports that HEALIOS K.K., its development and commercial partner in Japan, provided an update earlier this morning regarding its clinical programs for acute respiratory distress syndrome and ischemic stroke involving MultiStem® in its FY2021 Q3 financial results presentation.

Johnson & Johnson announced its intent to separate the Company’s Consumer Health business, creating a new publicly traded company.

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will present translational data from the Phase 1 SURPASS trial during the poster session at the Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C. (or virtual) (Abstract #373) from November 12-14, 2021.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, reported financial results for the third quarter ended September 30, 2021.